David Moreno
Concepts (296)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 7 | 2025 | 14 | 3.930 |
Why?
| | Multiple Myeloma | 13 | 2025 | 252 | 3.230 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 4 | 2025 | 9 | 2.750 |
Why?
| | Lymphoma, B-Cell | 3 | 2023 | 106 | 2.180 |
Why?
| | Saccharomyces cerevisiae | 12 | 2024 | 557 | 1.910 |
Why?
| | Saccharomyces cerevisiae Proteins | 10 | 2023 | 405 | 1.840 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2025 | 99 | 1.610 |
Why?
| | Cellular Senescence | 3 | 2024 | 189 | 1.330 |
Why?
| | Proteostasis | 2 | 2020 | 29 | 1.290 |
Why?
| | Immunoglobulin M | 5 | 2025 | 289 | 1.260 |
Why?
| | Molecular Chaperones | 3 | 2019 | 195 | 1.210 |
Why?
| | B-Cell Maturation Antigen | 5 | 2025 | 13 | 1.170 |
Why?
| | Immunotherapy, Adoptive | 6 | 2025 | 327 | 1.030 |
Why?
| | Plasmacytoma | 2 | 2022 | 16 | 0.970 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2025 | 21 | 0.930 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2025 | 59 | 0.920 |
Why?
| | Translocation, Genetic | 1 | 2025 | 105 | 0.880 |
Why?
| | Chromosome Aberrations | 1 | 2025 | 156 | 0.870 |
Why?
| | Calcaneus | 1 | 2022 | 31 | 0.750 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 43 | 0.750 |
Why?
| | Pharmaceutical Preparations | 2 | 2020 | 179 | 0.730 |
Why?
| | Galactokinase | 1 | 2020 | 4 | 0.700 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 97 | 0.690 |
Why?
| | Epistasis, Genetic | 1 | 2020 | 70 | 0.670 |
Why?
| | Automation | 1 | 2020 | 95 | 0.670 |
Why?
| | Cell Enlargement | 2 | 2019 | 7 | 0.660 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2025 | 622 | 0.660 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 158 | 0.640 |
Why?
| | Leishmania infantum | 4 | 2014 | 8 | 0.640 |
Why?
| | Graft vs Host Disease | 2 | 2019 | 252 | 0.630 |
Why?
| | DNA Replication | 2 | 2023 | 238 | 0.630 |
Why?
| | Bone Neoplasms | 1 | 2022 | 247 | 0.630 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2019 | 10 | 0.620 |
Why?
| | Cell Size | 1 | 2019 | 91 | 0.610 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 98 | 0.610 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1692 | 0.610 |
Why?
| | Histone Deacetylases | 1 | 2020 | 215 | 0.610 |
Why?
| | Time-Lapse Imaging | 1 | 2019 | 21 | 0.600 |
Why?
| | Intravital Microscopy | 1 | 2019 | 25 | 0.600 |
Why?
| | Heat-Shock Response | 1 | 2019 | 77 | 0.590 |
Why?
| | Chromatin | 1 | 2020 | 519 | 0.510 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 752 | 0.440 |
Why?
| | Receptors, Immunologic | 2 | 2025 | 216 | 0.420 |
Why?
| | Carbamates | 2 | 2010 | 50 | 0.410 |
Why?
| | Mutation | 5 | 2025 | 3958 | 0.390 |
Why?
| | Cyclins | 4 | 2021 | 91 | 0.380 |
Why?
| | Smoldering Multiple Myeloma | 2 | 2021 | 7 | 0.370 |
Why?
| | Receptors, CXCR4 | 2 | 2022 | 86 | 0.340 |
Why?
| | Imides | 1 | 2010 | 11 | 0.340 |
Why?
| | Antiprotozoal Agents | 1 | 2010 | 16 | 0.340 |
Why?
| | T-Lymphocytes | 3 | 2025 | 1996 | 0.340 |
Why?
| | Selenium | 1 | 2010 | 43 | 0.340 |
Why?
| | CDC28 Protein Kinase, S cerevisiae | 2 | 2021 | 7 | 0.340 |
Why?
| | Prognosis | 3 | 2025 | 4030 | 0.320 |
Why?
| | Dexamethasone | 2 | 2025 | 368 | 0.310 |
Why?
| | Humans | 39 | 2025 | 137585 | 0.310 |
Why?
| | Genomics | 2 | 2025 | 795 | 0.300 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2024 | 801 | 0.300 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2019 | 27 | 0.290 |
Why?
| | Small Molecule Libraries | 2 | 2020 | 94 | 0.270 |
Why?
| | Skin Neoplasms | 2 | 2023 | 855 | 0.260 |
Why?
| | Gene Expression Regulation, Fungal | 3 | 2023 | 72 | 0.250 |
Why?
| | Protein Biosynthesis | 4 | 2022 | 433 | 0.250 |
Why?
| | Signaling Lymphocytic Activation Molecule Family | 1 | 2025 | 7 | 0.240 |
Why?
| | Sulfonamides | 2 | 2024 | 513 | 0.230 |
Why?
| | Positive Regulatory Domain I-Binding Factor 1 | 1 | 2025 | 18 | 0.230 |
Why?
| | Hyperpigmentation | 1 | 2005 | 26 | 0.230 |
Why?
| | Bortezomib | 1 | 2025 | 54 | 0.230 |
Why?
| | Thalidomide | 1 | 2025 | 40 | 0.230 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2129 | 0.220 |
Why?
| | Remote Consultation | 1 | 2005 | 54 | 0.220 |
Why?
| | Histone Acetyltransferases | 1 | 2025 | 60 | 0.220 |
Why?
| | Aged | 10 | 2025 | 23961 | 0.220 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2025 | 98 | 0.220 |
Why?
| | Receptors, Virus | 1 | 2024 | 83 | 0.220 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 916 | 0.220 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2025 | 135 | 0.220 |
Why?
| | Neoplasm, Residual | 1 | 2025 | 133 | 0.220 |
Why?
| | Bone Marrow | 2 | 2024 | 286 | 0.220 |
Why?
| | Aged, 80 and over | 6 | 2025 | 7635 | 0.210 |
Why?
| | Cell Cycle | 3 | 2023 | 601 | 0.210 |
Why?
| | Disease-Free Survival | 2 | 2022 | 686 | 0.200 |
Why?
| | Middle Aged | 11 | 2025 | 33479 | 0.200 |
Why?
| | Quinazolines | 1 | 2024 | 251 | 0.200 |
Why?
| | Male | 17 | 2025 | 67762 | 0.190 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2024 | 224 | 0.190 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2021 | 7 | 0.190 |
Why?
| | Cell Cycle Proteins | 2 | 2023 | 617 | 0.190 |
Why?
| | Molecular Dynamics Simulation | 2 | 2020 | 213 | 0.190 |
Why?
| | Models, Molecular | 5 | 2020 | 1570 | 0.190 |
Why?
| | Drug Discovery | 2 | 2020 | 142 | 0.180 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2021 | 9 | 0.180 |
Why?
| | Allografts | 1 | 2022 | 146 | 0.180 |
Why?
| | Skin Diseases | 2 | 2018 | 149 | 0.180 |
Why?
| | Immunoglobulin Light Chains | 1 | 2021 | 47 | 0.180 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2021 | 83 | 0.180 |
Why?
| | Patient Selection | 1 | 2005 | 696 | 0.180 |
Why?
| | Endodeoxyribonucleases | 2 | 2014 | 72 | 0.170 |
Why?
| | Genes, Regulator | 1 | 2020 | 37 | 0.170 |
Why?
| | Dendritic Spines | 1 | 2021 | 65 | 0.170 |
Why?
| | Polymerase Chain Reaction | 2 | 2022 | 1062 | 0.170 |
Why?
| | Hydroxamic Acids | 1 | 2020 | 89 | 0.170 |
Why?
| | Cytoplasmic Granules | 1 | 2021 | 93 | 0.170 |
Why?
| | Models, Biological | 3 | 2024 | 1783 | 0.170 |
Why?
| | Female | 17 | 2025 | 73304 | 0.170 |
Why?
| | Calibration | 1 | 2020 | 146 | 0.170 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3412 | 0.170 |
Why?
| | Feedback, Physiological | 1 | 2020 | 77 | 0.160 |
Why?
| | Niacinamide | 1 | 2020 | 82 | 0.160 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2025 | 872 | 0.160 |
Why?
| | Epigenomics | 1 | 2020 | 115 | 0.160 |
Why?
| | Melanoma | 2 | 2024 | 760 | 0.160 |
Why?
| | Photopheresis | 1 | 2019 | 9 | 0.160 |
Why?
| | RNA, Messenger | 2 | 2025 | 2833 | 0.160 |
Why?
| | S Phase Cell Cycle Checkpoints | 1 | 2019 | 4 | 0.160 |
Why?
| | Treatment Outcome | 5 | 2025 | 10811 | 0.160 |
Why?
| | Cell Nucleolus | 1 | 2019 | 17 | 0.160 |
Why?
| | Luminescent Agents | 1 | 2019 | 7 | 0.150 |
Why?
| | Actins | 1 | 2021 | 416 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2022 | 385 | 0.150 |
Why?
| | Spatio-Temporal Analysis | 1 | 2019 | 34 | 0.150 |
Why?
| | Acute Disease | 2 | 2019 | 1007 | 0.150 |
Why?
| | Cyclin G1 | 1 | 2018 | 1 | 0.150 |
Why?
| | Lymphoma | 1 | 2020 | 208 | 0.150 |
Why?
| | Cell Growth Processes | 1 | 2018 | 52 | 0.150 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2019 | 73 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1079 | 0.150 |
Why?
| | Transcription, Genetic | 1 | 2025 | 1457 | 0.150 |
Why?
| | Spectrometry, Fluorescence | 1 | 2019 | 168 | 0.140 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 305 | 0.140 |
Why?
| | Centromere | 1 | 2018 | 59 | 0.140 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2019 | 132 | 0.140 |
Why?
| | Adenosine Triphosphatases | 1 | 2019 | 168 | 0.140 |
Why?
| | Luminescent Proteins | 1 | 2019 | 179 | 0.140 |
Why?
| | Stress, Physiological | 1 | 2021 | 443 | 0.140 |
Why?
| | Pleural Effusion | 1 | 2017 | 54 | 0.130 |
Why?
| | Macrophages | 1 | 2024 | 1547 | 0.130 |
Why?
| | Biological Evolution | 1 | 2020 | 474 | 0.130 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 660 | 0.120 |
Why?
| | Chronic Disease | 2 | 2019 | 1793 | 0.120 |
Why?
| | Disease Management | 3 | 2025 | 628 | 0.120 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1353 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1430 | 0.110 |
Why?
| | Mitochondria | 2 | 2014 | 948 | 0.110 |
Why?
| | Adult | 8 | 2025 | 37929 | 0.110 |
Why?
| | Endoplasmic Reticulum | 1 | 2017 | 265 | 0.110 |
Why?
| | Molecular Conformation | 3 | 2020 | 145 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2015 | 152 | 0.110 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1502 | 0.110 |
Why?
| | Exonucleases | 1 | 2014 | 9 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1483 | 0.110 |
Why?
| | Mice | 7 | 2025 | 17787 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 185 | 0.110 |
Why?
| | Endonucleases | 1 | 2014 | 32 | 0.110 |
Why?
| | Biomarkers | 1 | 2025 | 4149 | 0.110 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2013 | 18 | 0.100 |
Why?
| | Pyridones | 1 | 2015 | 168 | 0.100 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4295 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2017 | 594 | 0.100 |
Why?
| | Apoptosis | 2 | 2014 | 2553 | 0.100 |
Why?
| | Immunoglobulin A | 2 | 2025 | 211 | 0.090 |
Why?
| | Consensus | 2 | 2025 | 683 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2804 | 0.090 |
Why?
| | Signal Transduction | 2 | 2022 | 5079 | 0.090 |
Why?
| | Anti-HIV Agents | 2 | 2010 | 778 | 0.090 |
Why?
| | Parasitic Sensitivity Tests | 1 | 2010 | 3 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 90 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 238 | 0.080 |
Why?
| | HIV | 2 | 2010 | 234 | 0.080 |
Why?
| | Animals | 8 | 2025 | 36940 | 0.080 |
Why?
| | Gene Expression | 2 | 2019 | 1502 | 0.080 |
Why?
| | Organophosphates | 1 | 2010 | 134 | 0.080 |
Why?
| | Structure-Activity Relationship | 2 | 2024 | 570 | 0.080 |
Why?
| | Child | 5 | 2022 | 21935 | 0.070 |
Why?
| | Adolescent | 4 | 2022 | 21513 | 0.070 |
Why?
| | Protozoan Proteins | 1 | 2008 | 82 | 0.070 |
Why?
| | Peptides | 1 | 2013 | 985 | 0.070 |
Why?
| | Cell Survival | 1 | 2010 | 1120 | 0.070 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1276 | 0.060 |
Why?
| | Bronchogenic Cyst | 1 | 2005 | 7 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2008 | 620 | 0.060 |
Why?
| | Mouse Embryonic Stem Cells | 1 | 2025 | 30 | 0.060 |
Why?
| | Nectins | 1 | 2024 | 6 | 0.060 |
Why?
| | Cell Line | 1 | 2010 | 2847 | 0.060 |
Why?
| | Time Factors | 2 | 2017 | 6828 | 0.060 |
Why?
| | Hepatitis C | 1 | 2007 | 271 | 0.060 |
Why?
| | CRISPR-Cas Systems | 1 | 2025 | 125 | 0.050 |
Why?
| | HIV Infections | 2 | 2010 | 2836 | 0.050 |
Why?
| | RNA Stability | 1 | 2025 | 117 | 0.050 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2005 | 230 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2025 | 601 | 0.050 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2023 | 41 | 0.050 |
Why?
| | HIV-1 | 2 | 2010 | 864 | 0.050 |
Why?
| | RNA Splicing | 1 | 2025 | 269 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2024 | 138 | 0.050 |
Why?
| | Mice, Nude | 1 | 2024 | 698 | 0.050 |
Why?
| | Biological Transport | 1 | 2023 | 418 | 0.050 |
Why?
| | Longevity | 1 | 2023 | 165 | 0.050 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2010 | 271 | 0.050 |
Why?
| | Child, Preschool | 4 | 2017 | 11074 | 0.050 |
Why?
| | Recurrence | 1 | 2025 | 1060 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2022 | 156 | 0.050 |
Why?
| | Rats | 2 | 2024 | 5647 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 313 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2021 | 224 | 0.040 |
Why?
| | Iron | 1 | 2023 | 313 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 84 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 191 | 0.040 |
Why?
| | Trans-Activators | 1 | 2023 | 398 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5131 | 0.040 |
Why?
| | Th17 Cells | 1 | 2022 | 108 | 0.040 |
Why?
| | Intrinsically Disordered Proteins | 1 | 2021 | 34 | 0.040 |
Why?
| | History, 21st Century | 1 | 2021 | 213 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2021 | 103 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 307 | 0.040 |
Why?
| | Inflammasomes | 1 | 2022 | 131 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 404 | 0.040 |
Why?
| | History, 20th Century | 1 | 2021 | 325 | 0.040 |
Why?
| | Databases, Protein | 1 | 2020 | 85 | 0.040 |
Why?
| | Molecular Weight | 1 | 2020 | 335 | 0.040 |
Why?
| | Quantum Theory | 1 | 2020 | 78 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2021 | 217 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2019 | 17 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2019 | 46 | 0.040 |
Why?
| | HeLa Cells | 1 | 2021 | 636 | 0.040 |
Why?
| | Glucose | 1 | 2024 | 1020 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 362 | 0.040 |
Why?
| | Colitis | 1 | 2022 | 266 | 0.040 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 119 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2022 | 427 | 0.040 |
Why?
| | Neuronal Plasticity | 1 | 2021 | 290 | 0.040 |
Why?
| | Disease Progression | 2 | 2021 | 2757 | 0.040 |
Why?
| | Rituximab | 1 | 2019 | 176 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 2 | 2010 | 269 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1325 | 0.040 |
Why?
| | Immunotherapy | 1 | 2023 | 641 | 0.040 |
Why?
| | G1 Phase | 1 | 2018 | 71 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 664 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1809 | 0.040 |
Why?
| | Saccharomycetales | 1 | 2018 | 27 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2022 | 1142 | 0.030 |
Why?
| | Piperidines | 1 | 2019 | 206 | 0.030 |
Why?
| | Proteolysis | 1 | 2018 | 177 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1389 | 0.030 |
Why?
| | Adenine | 1 | 2019 | 271 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 893 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2139 | 0.030 |
Why?
| | Viral Load | 2 | 2010 | 466 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 644 | 0.030 |
Why?
| | Spain | 2 | 2007 | 41 | 0.030 |
Why?
| | Cell Division | 1 | 2018 | 794 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1242 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2900 | 0.030 |
Why?
| | Pyrazoles | 1 | 2019 | 423 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 470 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 500 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5742 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2607 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 1396 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1719 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 174 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1357 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 2224 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 410 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1972 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1009 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 1991 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1066 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1266 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2018 | 712 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2015 | 476 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3196 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 653 | 0.020 |
Why?
| | Administration, Oral | 1 | 2015 | 816 | 0.020 |
Why?
| | Brain | 1 | 2024 | 2668 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 375 | 0.020 |
Why?
| | Neurons | 1 | 2021 | 1590 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2017 | 1993 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 192 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 5757 | 0.020 |
Why?
| | Pneumonia | 1 | 2017 | 639 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2057 | 0.020 |
Why?
| | Furans | 1 | 2010 | 24 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 431 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7604 | 0.020 |
Why?
| | Protein Sorting Signals | 1 | 2008 | 20 | 0.020 |
Why?
| | Deoxyribonucleases | 1 | 2008 | 24 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2008 | 343 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2019 | 15657 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2475 | 0.020 |
Why?
| | Protein Transport | 1 | 2008 | 445 | 0.020 |
Why?
| | RNA, Viral | 1 | 2010 | 656 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 861 | 0.020 |
Why?
| | Hepacivirus | 1 | 2007 | 261 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1050 | 0.010 |
Why?
| | Infant | 1 | 2007 | 9465 | 0.010 |
Why?
|
|
Moreno's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|